• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Aim The guideline for coronary artery revascularization replaces the 2011 coronary artery
bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines …

Aim: The executive summary of the American College of Cardiology/American Heart
Association/Society for Cardiovascular Angiography and Interventions coronary artery …

Although substantial progress has been made in the diagnosis and treatment of acute
coronary syndromes, cardiovascular disease remains the leading cause of death globally …

2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Importance Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after
percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with …

Importance Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was
evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy …

Objective To assess the risks and benefits of P2Y 12 inhibitor monotherapy compared with
dual antiplatelet therapy (DAPT) and whether these associations are modified by patients' …